Pelthos Therapeutics posts investor deck outlining dermatology portfolio strategy centered on Zelsuvmi launch, Xepi and Xeglyze additions
PTHS•Launch timing for Xepi and Xeglyze
- Xepi relaunch is targeted for Q1 2027.
- Xeglyze commercial launch is planned for Q3 2027.
Key equity and balance sheet metrics
- Key equity metrics as of 08/10/26: stock price $29; about 9,000,000 shares outstanding; market cap about $260 million.
- Cash at the end of Q2 2026 totaled $24.2 million.
- 60-day average daily trading volume was about 51,000 shares.
Investor deck highlights Zelsuvmi traction and portfolio strategy
Pelthos Therapeutics posts investor deck outlining dermatology portfolio strategy centered on Zelsuvmi launch, Xepi and Xeglyze additions.
- Pelthos highlighted commercial traction for Zelsuvmi, with more than 20,000 units dispensed since the July 2025 launch through April 2026.
- Portfolio expansion is centered on two FDA-approved dermatology assets, Xepi for impetigo and Xeglyze for head lice, to leverage existing infrastructure.
